Clearside Biomedical, Inc. (CLSDQ): Nasdaq/NYSE listing notice — Clearside Biomedical gets Nasdaq MVLS deficiency notice; stockholders approve reverse stock split

Clearside Biomedical, Inc.

Received Nasdaq notice on Aug 28, 2025 for non-compliance with $50M MVLS requirement for continued listing on Global Market.
Company has 180 days until Feb 24, 2026 to regain compliance; may consider transfer to Nasdaq Capital Market.
At special meeting Aug 29, 2025, stockholders approved reverse stock split in range of 1-for-5 to 1-for-15 to address bid price deficiency.
Reverse stock split approved with 46.5M for, 2.2M against, 459k abstained out of 49.2M shares present.

item 3.01 item 5.07

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Clearside Biomedical, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A)

Exact text from the filing

August 28, 2025, Clearside Biomedical, Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with the minimum Market Value of Listed Securities (“ MVLS ”) of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “ MVLS Requirement ”). The notice has no present impact on the listing of the Company’s securities on the Nasdaq Global Market. Under Nasdaq Listing Rule 5810(c

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-194994

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.